Remdesivir, a drug that blocks a virus enzyme, According to experts, it allows rapid recovery of patients diagnosed with coronavirus, “The data shows that remdesivir has a clear, significant and positive effect to decrease recovery time”said Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases.
Emory University in Georgia He is part of the medical team testing the remdesivir drug that until now has been used mainly to treat Ebola patients.
Emory was the leader in the clinical trial and had the largest number of participants in the study that includes more than 1,000 people worldwide.
“This is an important development,” said Dr. Aneesh Mehta, chief of infectious disease services at Emory University Hospital.
Doctors say the drug works by blocking the virus’s ability to make more of itself and develop inside the body.
Mehta said that while this is not a vaccine, the drug is a major step forward in the fight against the coronavirus pandemic.
“Remdesivir is the first therapeutic drug, the first drug to show a positive effect in patients with COVID-19”, Mehta said, who also added that “It may decrease the overall mortality of patients with COVID-19, but again, we need a lot more data for any of those judgments to become more specific. We will get that data in the coming weeks.”.
All patients who are part of the trial have been hospitalized and show moderate to severe symptoms of coronavirus.
The lead researcher says that now the drug’s potential impact could save lives.
“That helps us shorten the amount of time the patient needs to be in the hospital and receive medical attention, and it decreases the chance of developing complications from their COVID-19 infection,” Mehta said.
There is cautious optimism about these data, and doctors say they need more complete information in the coming weeks.
“It is an additional tool to help us improve our patients and get them home to their families faster,” said Mehta.